Drug Profile


Alternative Names: HyLeukin; HyLeukin-7; IL-7-hyFc; Interleukin-7-hybrid-Fc-recombinant-protein; NT-I7

Latest Information Update: 23 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genexine
  • Developer Genexine; NeoImmuneTech
  • Class Antineoplastics; Immunoglobulin Fc fragments; Interleukins; Recombinant proteins
  • Mechanism of Action Interleukin 7 receptor agonists; Lymphocyte modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Leucopenia
  • New Molecular Entity No

Highest Development Phases

  • Phase I Cervical intraepithelial neoplasia; Glioblastoma; Human papillomavirus infections; Leucopenia; Solid tumours

Most Recent Events

  • 18 Jul 2018 Genexine enters into a collaboration with Merck for a phase Ib/II trial in Breast cancer (Combination therapy)
  • 25 May 2018 Phase-I clinical trials in Glioblastoma in USA (unspecified route)
  • 01 May 2018 NeoImmuneTech, Genexine and Roche agree to co-develop GX I7 for Skin cancer (Combination therapy, Late-stage disease)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top